Absolute abundance and function of intestinal drug transporters: A prerequisite for fully mechanistic in vitro-in vivo extrapolation of oral drug absorption

Biopharmaceutics and Drug Disposition

Volumn 34, Issue 1, 2013, Pages 2-28

  Harwood, M D ^a,b   Neuhoff, S ^a   Carlson, G L ^b   Warhurst, G ^b   Rostami Hodjegan, A ^a,c  

^a CERTARA UK LIMITED   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

absolute abundance; drug transporters; human intestine; ISEF T; IVIVE; modelling and simulation; PBPK; transporter scaling

Indexed keywords

ACICLOVIR; BREAST CANCER RESISTANCE PROTEIN; DRUG METABOLIZING ENZYME; MARAVIROC; MEMBRANE RECEPTOR; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 2; QUINIDINE; TALINOLOL; VALACICLOVIR; VERAPAMIL; VINBLASTINE;

ACTIVE TRANSPORT; APICAL MEMBRANE; AREA UNDER THE CURVE; BASOLATERAL MEMBRANE; CELL FRACTIONATION; COMPUTER MODEL; COMPUTER SIMULATION; DRUG ABSORPTION; DRUG BINDING SITE; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DEGRADATION; DRUG DISPOSITION; DRUG INDUSTRY; DRUG MECHANISM; DRUG PENETRATION; DRUG SOLUBILITY; DRUG TISSUE LEVEL; DRUG TRANSPORT; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INTESTINE ABSORPTION; INTESTINE BRUSH BORDER MEMBRANE; INTESTINE CELL; MATHEMATICAL MODEL; MAXIMUM PLASMA CONCENTRATION; MICHAELIS CONSTANT; MICHAELIS MENTEN KINETICS; NONHUMAN; PHYSICAL CHEMISTRY; PLASMA PROTEIN BINDING; PREDICTIVE VALUE; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; TIME TO MAXIMUM PLASMA CONCENTRATION; TRANSPORT KINETICS;

ANIMALS; BIOLOGICAL TRANSPORT; DRUG DESIGN; DRUG INDUSTRY; HUMANS; INTESTINAL ABSORPTION; MEMBRANE TRANSPORT PROTEINS; MODELS, BIOLOGICAL; PHARMACEUTICAL PREPARATIONS;

EID: 84872680624     PISSN: 01422782     EISSN: 1099081X     Source Type: Journal    
DOI: 10.1002/bdd.1810     Document Type: Review

References (145)

1. Huang SM,. PBPK as a tool in regulatory review. Biopharm Drug Dispos 2012; 33: 51-52.
2. Rostami-Hodjegan A, Tamai I, Pang KS,. Physiologically based pharmacokinetic (PBPK) modeling: it is here to stay!. Biopharm Drug Dispos 2012; 33: 47-50.
3. Smith BJ,. An industrial perspective on contemporary applications of PBPK models in drug discovery and development. Biopharm Drug Dispos 2012; 33: 53-54.
4. Giacomini KM, Huang SM, Tweedie DJ, et al,. Membrane transporters in drug development. Nat Rev Drug Discov 2010; 9: 215-236.
5. CHMP. Guidance on the Investigation of Drug Interactions. European Medicines Agency: 2012. http://www.ema.europa.eu/docs/en-GB/document-library/ Scientific-guideline/2012/07/WC500129606.pdf [18 July 2012].
6. Varum FJ, Merchant HA, Basit AW,. Oral modified-release formulations in motion: the relationship between gastrointestinal transit and drug absorption. Int J Pharm 2010; 395: 26-36.
7. Benet LZ,. The drug transporter-metabolism alliance: uncovering and defining the interplay. Mol Pharm 2009; 6: 1631-1643.
8. Rodrigues AC,. Efflux and uptake transporters as determinants of statin response. Expert Opin Drug Metab Toxicol 2010; 6: 621-632.
9. Pang KS,. Modeling of intestinal drug absorption: roles of transporters and metabolic enzymes (for the Gillette Review Series). Drug Metab Dispos 2003; 31: 1507-1519.
10. Poulin P, Theil FP,. Prediction of pharmacokinetics prior to in vivo studies. 1. Mechanism-based prediction of volume of distribution. J Pharm Sci 2002; 91: 129-156.
11. Rodgers T, Rowland M,. Mechanistic approaches to volume of distribution predictions: understanding the processes. Pharm Res 2007; 24: 918-933.
12. Jamei M, Dickinson GL, Rostami-Hodjegan A,. A framework for assessing inter-individual variability in pharmacokinetics using virtual human populations and integrating general knowledge of physical chemistry, biology, anatomy, physiology and genetics: A tale of 'bottom-up' vs 'top-down' recognition of covariates. Drug Metab Pharmacokinet 2009; 24: 53-75.
13. Jamei M, Marciniak S, Feng K, Barnett A, Tucker G, Rostami-Hodjegan A,. The Simcyp population-based ADME simulator. Expert Opin Drug Metab Toxicol 2009; 5: 211-223.
14. Jamei M, Turner D, Yang J, et al,. Population-based mechanistic prediction of oral drug absorption. AAPS J 2009; 11: 225-237.
15. Bolger MB, Lukacova V, Woltosz WS,. Simulations of the nonlinear dose dependence for substrates of influx and efflux transporters in the human intestine. AAPS J 2009; 11: 353-363.
16. Darwich AS, Neuhoff S, Jamei M, Rostami-Hodjegan A,. Interplay of metabolism and transport in determining oral drug absorption and gut wall metabolism: a simulation assessment using the 'Advanced Dissolution, Absorption, Metabolism (ADAM)' model. Curr Drug Metab 2010; 11: 716-729.
17. Chen Y, Liu L, Nguyen K, Fretland AJ,. Utility of intersystem extrapolation factors in early reaction phenotyping and the quantitative extrapolation of human liver microsomal intrinsic clearance using recombinant cytochromes P450. Drug Metab Dispos 2011; 39: 373-382.
18. Rowland M, Peck C, Tucker G,. Physiologically-based pharmacokinetics in drug development and regulatory science. Annu Rev Pharmacol Toxicol 2011; 51: 45-73.
19. Muller F, Fromm MF,. Transporter-mediated drug-drug interactions. Pharmacogenomics 2011; 12: 1017-1037.
20. 50 criteria in the P-gp decision tree. J Clin Pharmacol 2012. DOI: 10.117/0091270011436344
21. Lennernäs H,. Intestinal permeability and its relevance for absorption and elimination. Xenobiotica 2007; 37: 1015-1051.
22. Varma MV, Ambler CM, Ullah M, et al,. Targeting intestinal transporters for optimizing oral drug absorption. Curr Drug Metab 2010; 11: 730-742.
23. Wetterich U, Spahn-Langguth H, Mutschler E, Terhaag B, Rosch W, Langguth P,. Evidence for intestinal secretion as an additional clearance pathway of talinolol enantiomers: concentration- and dose-dependent absorption in vitro and in vivo. Pharm Res 1996; 13: 514-522.
24. Abel S, van der Ryst E, Rosario MC, et al,. Assessment of the pharmacokinetics, safety and tolerability of maraviroc, a novel CCR5 antagonist, in healthy volunteers. Br J Clin Pharmacol 2008; 65 (Suppl 1): 5-18.
25. Zembruski NC, Buchel G, Jodicke L, Herzog M, Haefeli WE, Weiss J,. Potential of novel antiretrovirals to modulate expression and function of drug transporters in vitro. J Antimicrob Chemother 2011; 66: 802-812.
26. Weller S, Blum MR, Doucette M, et al,. Pharmacokinetics of the acyclovir pro-drug valaciclovir after escalating single- and multiple-dose administration to normal volunteers. Clin Pharmacol Ther 1993; 54: 595-605.
27. Maeda K, Ikeda Y, Fujita T, et al,. Identification of the rate-determining process in the hepatic clearance of atorvastatin in a clinical cassette microdosing study. Clin Pharmacol Ther 2011; 90: 575-581.
28. Yamane N, Tozuka Z, Sugiyama Y, Tanimoto T, Yamazaki A, Kumagai Y,. Microdose clinical trial: quantitative determination of fexofenadine in human plasma using liquid chromatography/electrospray ionization tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2007; 858: 118-128.
29. Zhang L, Huang SM, Lesko LJ,. Transporter-mediated drug-drug interactions. Clin Pharmacol Ther 2011; 89: 481-484.
30. CDER. Guidance for Industry. Drug Interaction Studies-Study Design, Data Analysis, Implications for Dosing, and Labeling Recommendations. Food and Drug Admininstration, US Department of Health and Human Services: February 2012. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/ Guidances/ucm292362.pdf [1 April 2012].
31. Thelen K, Dressman JB,. Cytochrome P450-mediated metabolism in the human gut wall. J Pharm Pharmacol 2009; 61: 541-558.
32. Ritter JK,. Intestinal UGTs as potential modifiers of pharmacokinetics and biological responses to drugs and xenobiotics. Expert Opin Drug Metab Toxicol 2007; 3: 93-107.
33. Riches Z, Stanley EL, Bloomer JC, Coughtrie MW,. Quantitative evaluation of the expression and activity of five major sulfotransferases (SULTs) in human tissues: the SULT 'pie'. Drug Metab Dispos 2009; 37: 2255-2261.
34. Grandvuinet AS, Vestergaard HT, Rapin N, Steffansen B,. Intestinal transporters for endogenic and pharmaceutical organic anions: the challenges of deriving in vitro kinetic parameters for the prediction of clinically relevant drug-drug interactions. J Pharm Pharmacol 2012: Accepted Article.
35. Artursson P, Palm K, Luthman K,. Caco-2 monolayers in experimental and theoretical predictions of drug transport. Adv Drug Deliv Rev 2001; 46: 27-43.
36. 50, that allow for the exclusion of drug candidates from clinical digoxin interaction studies. Mol Pharm 2010; 7: 398-411.
37. Kell DB, Dobson PD, Oliver SG,. Pharmaceutical drug transport: the issues and the implications that it is essentially carrier-mediated only. Drug Discov Today 2011; 16: 704-714.
38. Hilgendorf C, Ahlin G, Seithel A, Artursson P, Ungell AL, Karlsson J,. Expression of thirty-six drug transporter genes in human intestine, liver, kidney, and organotypic cell lines. Drug Metab Dispos 2007; 35: 1333-1340.
39. Korzekwa K, Nagar S, Tucker J, Weiskircher EA, Bhoopathy S, Hidalgo IJ,. Models to predict unbound intracellular drug concentrations in the presence of transporters. Drug Metab Dispos 2012; 40: 865-876.
40. Matsson P, Pedersen JM, Norinder U, Bergstrom CA, Artursson P,. Identification of novel specific and general inhibitors of the three major human ATP-binding cassette transporters P-gp, BCRP and MRP2 among registered drugs. Pharm Res 2009; 26: 1816-1831.
41. Neuhoff S, Artursson P, Zamora I, Ungell AL,. Impact of extracellular protein binding on passive and active drug transport across Caco-2 cells. Pharm Res 2006; 23: 350-359.
42. Stephens RH, O'Neill CA, Warhurst A, Carlson GL, Rowland M, Warhurst G,. Kinetic profiling of P-glycoprotein-mediated drug efflux in rat and human intestinal epithelia. J Pharmacol Exp Ther 2001; 296: 584-591.
43. Li N, Nemirovskiy OV, Zhang Y, et al,. Absolute quantification of multidrug resistance-associated protein 2 (MRP2/ABCC2) using liquid chromatography tandem mass spectrometry. Anal Biochem 2008; 380: 211-222.
44. Zhang Y, Li N, Brown PW, Ozer JS, Lai Y,. Liquid chromatography/tandem mass spectrometry based targeted proteomics quantification of P-glycoprotein in various biological samples. Rapid Commun Mass Spectrom 2011; 25: 1715-1724.
45. Di L, Whitney-Pickett C, Umland JP, et al,. Development of a new permeability assay using low-efflux MDCKII cells. J Pharm Sci 2011; 100: 4974-4985.
46. Artursson P, Karlsson J,. Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells. Biochem Biophys Res Commun 1991; 175: 880-885.
47. Tang F, Horie K, Borchardt RT,. Are MDCK cells transfected with the human MDR1 gene a good model of the human intestinal mucosa? Pharm Res 2002; 19: 765-772.
48. Troutman MD, Thakker DR,. Efflux ratio cannot assess P-glycoprotein- mediated attenuation of absorptive transport: asymmetric effect of P-glycoprotein on absorptive and secretory transport across Caco-2 cell monolayers. Pharm Res 2003; 20: 1200-1209.
49. Horie K, Tang F, Borchardt RT,. Isolation and characterization of Caco-2 subclones expressing high levels of multidrug resistance protein efflux transporter. Pharm Res 2003; 20: 161-168.
50. Balakrishnan A, Hussainzada N, Gonzalez P, Bermejo M, Swaan PW, Polli JE,. Bias in estimation of transporter kinetic parameters from overexpression systems: Interplay of transporter expression level and substrate affinity. J Pharmacol Exp Ther 2007; 320: 133-144.
51. Shirasaka Y, Sakane T, Yamashita S,. Effect of P-glycoprotein expression levels on the concentration-dependent permeability of drugs to the cell membrane. J Pharm Sci 2008; 97: 553-565.
52. Aller SG, Yu J, Ward A, et al,. Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding. Science 2009; 323: 1718-1722.
53. m value of efflux pump substrates. Drug Metab Dispos 2007; 35: 1574-1579.
54. Soars MG, Grime K, Sproston JL, Webborn PJ, Riley RJ,. Use of hepatocytes to assess the contribution of hepatic uptake to clearance in vivo. Drug Metab Dispos 2007; 35: 859-865.
55. Gether U, Andersen PH, Larsson OM, Schousboe A,. Neurotransmitter transporters: molecular function of important drug targets. Trends Pharmacol Sci 2006; 27: 375-383.
56. Leuthold S, Hagenbuch B, Mohebbi N, Wagner CA, Meier PJ, Stieger B,. Mechanisms of pH-gradient driven transport mediated by organic anion polypeptide transporters. Am J Physiol Cell Physiol 2009; 296: C570-C582.
57. Abuasal BS, Bolger MB, Walker DK, Kaddoumi A,. In silico modeling for the non-linear absorption kinetics of UK-343,664: a P-gp and CYP3A4 substrate. Mol Pharm 2012; 9: 492-504.
58. Kalvass JC, Pollack GM,. Kinetic considerations for the quantitative assessment of efflux activity and inhibition: implications for understanding and predicting the effects of efflux inhibition. Pharm Res 2007; 24: 265-276.
59. Tachibana T, Kitamura S, Kato M, et al,. Model analysis of the concentration-dependent permeability of P-gp substrates. Pharm Res 2010; 27: 442-446.
60. Proctor WR, Bourdet DL, Thakker DR,. Mechanisms underlying saturable intestinal absorption of metformin. Drug Metab Dispos 2008; 36: 1650-1658.
61. Rolsted K, Rapin N, Steffansen B,. Simulating kinetic parameters in transporter mediated permeability across Caco-2 cells. A case study of estrone-3-sulfate. Eur J Pharm Sci 2011; 44: 218-226.
62. Sugano K, Shirasaka Y, Yamashita S,. Estimation of Michaelis-Menten constant of efflux transporter considering asymmetric permeability. Int J Pharm 2011; 418: 161-167.
63. Heikkinen AT, Korjamo T, Lepikko V, Monkkonen J,. Effects of experimental setup on the apparent concentration dependency of active efflux transport in in vitro cell permeation experiments. Mol Pharm 2010; 7: 605-617.
64. Sun H, Zhang L, Chow EC, Lin G, Zuo Z, Pang KS,. A catenary model to study transport and conjugation of baicalein, a bioactive flavonoid, in the Caco-2 cell monolayer: demonstration of substrate inhibition. J Pharmacol Exp Ther 2008; 326: 117-126.
65. Austin RP, Barton P, Mohmed S, Riley RJ,. The binding of drugs to hepatocytes and its relationship to physicochemical properties. Drug Metab Dispos 2005; 33: 419-425.
66. Rodgers T, Leahy D, Rowland M,. Physiologically based pharmacokinetic modeling 1: predicting the tissue distribution of moderate-to-strong bases. J Pharm Sci 2005; 94: 1259-1276.
67. Oehlke J, Ehrlich A, Krause E, Pritz S, Wiesner B, Beyermann M,. Growth factor- and adhesion protein-like components of fetal calf serum can significantly enhance the intracellular delivery of peptide nucleic acids. Nucleic Acid Ther 2011; 21: 285-291.
68. Reinoso RF, Telfer BA, Brennan BS, Rowland M,. Uptake of teicoplanin by isolated rat hepatocytes: comparison with in vivo hepatic distribution. Drug Metab Dispos 2001; 29: 453-459.
69. Bouzom F, Ball K, Perdaems N, Walther B,. Physiologically based pharmacokinetic (PBPK) modelling tools: how to fit with our needs? Biopharm Drug Dispos 2012; 33: 55-71.
70. Yu LX, Lipka E, Crison JR, Amidon GL,. Transport approaches to the biopharmaceutical design of oral drug delivery systems: prediction of intestinal absorption. Adv Drug Deliv Rev 1996; 19: 359-376.
71. Yu LX, Amidon GL,. Saturable small intestinal drug absorption in humans: modeling and interpretation of cefatrizine data. Eur J Pharm Biopharm 1998; 45: 199-203.
72. Barter ZE, Bayliss MK, Beaune PH, et al,. Scaling factors for the extrapolation of in vivo metabolic drug clearance from in vitro data: reaching a consensus on values of human microsomal protein and hepatocellularity per gram of liver. Curr Drug Metab 2007; 8: 33-45.
73. Tucker TG, Milne AM, Fournel-Gigleux S, Fenner KS, Coughtrie MW,. Absolute immunoquantification of the expression of ABC transporters P-glycoprotein, breast cancer resistance protein and multidrug resistance-associated protein 2 in human liver and duodenum. Biochem Pharmacol 2012; 83: 279-285.
74. Deo AK, Prasad B, Balogh L, Lai Y, Unadkat JD,. Interindividual variability in hepatic expression of the multidrug resistance-associated protein 2 (MRP2/ABCC2): quantification by liquid chromatography/tandem mass spectrometry. Drug Metab Dispos 2012; 40: 852-855.
75. Merino G, van Herwaarden AE, Wagenaar E, Jonker JW, Schinkel AH,. Sex-dependent expression and activity of the ATP-binding cassette transporter breast cancer resistance protein (BCRP/ABCG2) in liver. Mol Pharmacol 2005; 67: 1765-1771.
76. Niemi M,. Transporter pharmacogenetics and statin toxicity. Clin Pharmacol Ther 2010; 87: 130-133.
77. Ameyaw MM, Regateiro F, Li T, et al,. MDR1 pharmacogenetics: frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity. Pharmacogenetics 2001; 11: 217-221.
78. Greiner B, Eichelbaum M, Fritz P, et al,. The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. J Clin Invest 1999; 104: 147-153.
79. Mouly S, Paine MF,. P-glycoprotein increases from proximal to distal regions of human small intestine. Pharm Res 2003; 20: 1595-1599.
80. Bruyere A, Decleves X, Bouzom F, et al,. Effect of variations in the amounts of P-glycoprotein (ABCB1), BCRP (ABCG2) and CYP3A4 along the human small intestine on PBPK models for predicting intestinal first pass. Mol Pharm 2010; 7: 1596-1607.
81. Badhan R, Penny J, Galetin A, Houston JB,. Methodology for development of a physiological model incorporating CYP3A and P-glycoprotein for the prediction of intestinal drug absorption. J Pharm Sci 2009; 98: 2180-2197.
82. Zimmermann C, Gutmann H, Hruz P, Gutzwiller JP, Beglinger C, Drewe J,. Mapping of multidrug resistance gene 1 and multidrug resistance-associated protein isoform 1 to 5 mRNA expression along the human intestinal tract. Drug Metab Dispos 2005; 33: 219-224.
83. Albermann N, Schmitz-Winnenthal FH, Z'Graggen K, et al,. Expression of the drug transporters MDR1/ABCB1, MRP1/ABCC1, MRP2/ABCC2, BCRP/ABCG2, and PXR in peripheral blood mononuclear cells and their relationship with the expression in intestine and liver. Biochem Pharmacol 2005; 70: 949-958.
84. Seithel A, Karlsson J, Hilgendorf C, Bjorquist A, Ungell AL,. Variability in mRNA expression of ABC- and SLC-transporters in human intestinal cells: comparison between human segments and Caco-2 cells. Eur J Pharm Sci 2006; 28: 291-299.
85. Englund G, Rorsman F, Ronnblom A, et al,. Regional levels of drug transporters along the human intestinal tract: co-expression of ABC and SLC transporters and comparison with Caco-2 cells. Eur J Pharm Sci 2006; 29: 269-277.
86. Fromm MF, Kauffmann HM, Fritz P, et al,. The effect of rifampin treatment on intestinal expression of human MRP transporters. Am J Pathol 2000; 157: 1575-1580.
87. Glaeser H,. In Vivo Investigations Regarding the Importance of Intestinal Drug Metabolism and Transport in Humans. Dr. Margarete Fischer-Bosch Institute for Clinical Pharmacology, University of Stuttgart: Stuttgart, 2003; PhD Thesis.
88. Oswald S, Haenisch S, Fricke C, et al,. Intestinal expression of P-glycoprotein (ABCB1), multidrug resistance associated protein 2 (ABCC2), and uridine diphosphate-glucuronosyltransferase 1A1 predicts the disposition and modulates the effects of the cholesterol absorption inhibitor ezetimibe in humans. Clin Pharmacol Ther 2006; 79: 206-217.
89. Gutmann H, Hruz P, Zimmermann C, Beglinger C, Drewe J,. Distribution of breast cancer resistance protein (BCRP/ABCG2) mRNA expression along the human GI tract. Biochem Pharmacol 2005; 70: 695-699.
90. Urquhart BL, Ware JA, Tirona RG, et al,. Breast cancer resistance protein (ABCG2) and drug disposition: intestinal expression, polymorphisms and sulfasalazine as an in vivo probe. Pharmacogenet Genomics 2008; 18: 439-448.
91. Dietrich CG, Geier A, Salein N, et al,. Consequences of bile duct obstruction on intestinal expression and function of multidrug resistance-associated protein 2. Gastroenterology 2004; 126: 1044-1053.
92. von Richter O,. Expression and Function of Drug Metabolizing Enzymes and the ABC Transporter P-Glycoprotein in the Small Intestine and Liver of Humans. The Faculty of Chemistry and Pharmacy, Eberhard Karls University: Tübingen, 2000; PhD Thesis.
93. Berggren S, Gall C, Wollnitz N, et al,. Gene and protein expression of P-glycoprotein, MRP1, MRP2, and CYP3A4 in the small and large human intestine. Mol Pharm 2007; 4: 252-257.
94. Troutman MD, Thakker DR,. Novel experimental parameters to quantify the modulation of absorptive and secretory transport of compounds by P-glycoprotein in cell culture models of intestinal epithelium. Pharm Res 2003; 20: 1210-1224.
95. Cubitt HE, Yeo KR, Howgate EM, Rostami-Hodjegan A, Barter ZE,. Sources of interindividual variability in IVIVE of clearance: an investigation into the prediction of benzodiazepine clearance using a mechanistic population-based pharmacokinetic model. Xenobiotica 2011; 41: 623-638.
96. Canaparo R, Finnstrom N, Serpe L, et al,. Expression of CYP3A isoforms and P-glycoprotein in human stomach, jejunum and ileum. Clin Exp Pharmacol Physiol 2007; 34: 1138-1144.
97. Proctor NJ, Tucker GT, Rostami-Hodjegan A,. Predicting drug clearance from recombinantly expressed CYPs: intersystem extrapolation factors. Xenobiotica 2004; 34: 151-178.
98. Brun V, Masselon C, Garin J, Dupuis A,. Isotope dilution strategies for absolute quantitative proteomics. J Proteomics 2009; 72: 740-749.
99. Ohtsuki S, Uchida Y, Kubo Y, Terasaki T,. Quantitative targeted absolute proteomics-based ADME research as a new path to drug discovery and development: methodology, advantages, strategy, and prospects. J Pharm Sci 2011; 100: 3547-3559.
100. Pratt JM, Simpson DM, Doherty MK, Rivers J, Gaskell SJ, Beynon RJ,. Multiplexed absolute quantification for proteomics using concatenated signature peptides encoded by QconCAT genes. Nat Protoc 2006; 1: 1029-1043.
101. Li N, Zhang Y, Hua F, Lai Y,. Absolute difference of hepatobiliary transporter multidrug resistance-associated protein (MRP2/Mrp2) in liver tissues and isolated hepatocytes from rat, dog, monkey, and human. Drug Metab Dispos 2009; 37: 66-73.
102. Li N, Palandra J, Nemirovskiy OV, Lai Y,. LC-MS/MS mediated absolute quantification and comparison of bile salt export pump and breast cancer resistance protein in livers and hepatocytes across species. Anal Chem 2009; 81: 2251-2259.
103. Ohtsuki S, Schaefer O, Kawakami H, et al,. Simultaneous absolute protein quantification of transporters, cytochromes P450, and UDP- glucuronosyltransferases as a novel approach for the characterization of individual human liver: comparison with mRNA levels and activities. Drug Metab Dispos 2012; 40: 83-92.
104. Uchida Y, Ohtsuki S, Katsukura Y, et al,. Quantitative targeted absolute proteomics of human blood-brain barrier transporters and receptors. J Neurochem 2011; 117: 333-345.
105. Sakamoto A, Matsumaru T, Ishiguro N, et al,. Reliability and robustness of simultaneous absolute quantification of drug transporters, cytochrome P450 enzymes, and Udp-glucuronosyltransferases in human liver tissue by multiplexed MRM/selected reaction monitoring mode tandem mass spectrometry with nano-liquid chromatography. J Pharm Sci 2011; 100: 4037-4043.
106. Niessen J, Jedlitschky G, Grube M, et al,. Expression of ABC-type transport proteins in human platelets. Pharmacogenet Genomics 2010; 20: 396-400.
107. Schaefer O, Ohtsuki S, Kawakami H, et al,. Absolute quantification and differential expression of drug transporters, cytochrome P450 enzymes, and UDP-glucuronosyltransferases in cultured primary human hepatocytes. Drug Metab Dispos 2012; 40: 93-103.
108. Shawahna R, Uchida Y, Decleves X, et al,. Transcriptomic and quantitative proteomic analysis of transporters and drug metabolizing enzymes in freshly isolated human brain microvessels. Mol Pharm 2011; 8: 1332-1341.
109. Balogh LM, Kimoto E, Chupka J, Zhang H, Lai Y,. Membrane protein quantification by peptide-based mass spectrometry approaches: studies on the organic anion-transporting polypeptide family. J Proteomics Bioinform 2012; 54: 1-5.
110. Kamiie J, Ohtsuki S, Iwase R, et al,. Quantitative atlas of membrane transporter proteins: development and application of a highly sensitive simultaneous LC/MS/MS method combined with novel in silico peptide selection criteria. Pharm Res 2008; 25: 1469-1483.
111. Ito K, Uchida Y, Ohtsuki S, et al,. Quantitative membrane protein expression at the blood-brain barrier of adult and younger cynomolgus monkeys. J Pharm Sci 2011; 100: 3939-3950.
112. Agarwal S, Uchida Y, Mittapalli RK, Sane R, Terasaki T, Elmquist WF,. Quantitative proteomics of transporter expression in brain capillary endothelial cells isolated from P-gp, BCRP, and P-gp/BCRP knockout mice. Drug Metab Dispos 2012; 40: 1164-1169.
113. Bi YA, Kimoto E, Sevidal S, et al,. In vitro evaluation of hepatic transporter-mediated clinical drug-drug interactions: hepatocyte model optimization and retrospective investigation. Drug Metab Dispos 2012; 40: 1085-1092.
114. Miliotis T, Ali L, Palm JE, et al,. Development of a highly sensitive method using liquid chromatography-multiple reaction monitoring to quantify membrane P-glycoprotein in biological matrices and relationship to transport function. Drug Metab Dispos 2011; 39: 2440-2449.
115. Ji C, Tschantz WR, Pfeifer ND, Ullah M, Sadagopan N,. Development of a multiplex UPLC-MRM MS method for quantification of human membrane transport proteins OATP1B1, OATP1B3 and OATP2B1 in in vitro systems and tissues. Anal Chim Acta 2012; 717: 67-76.
116. Uchida Y, Ohtsuki S, Kamiie J, Terasaki T,. Blood-brain barrier (BBB) pharmacoproteomics: reconstruction of in vivo brain distribution of 11 P-glycoprotein substrates based on the BBB transporter protein concentration, in vitro intrinsic transport activity, and unbound fraction in plasma and brain in mice. J Pharmacol Exp Ther 2011; 339: 579-588.
117. Bow DA, Perry JL, Miller DS, Pritchard JB, Brouwer KL,. Localization of P-gp (Abcb1) and Mrp2 (Abcc2) in freshly isolated rat hepatocytes. Drug Metab Dispos 2008; 36: 198-202.
118. Ulvestad M, Bjorquist P, Molden E, Asberg A, Andersson TB,. OATP1B1/1B3 activity in plated primary human hepatocytes over time in culture. Biochem Pharmacol 2011; 82: 1219-1226.
119. Mirzaei H, McBee JK, Watts J, Aebersold R,. Comparative evaluation of current peptide production platforms used in absolute quantification in proteomics. Mol Cell Proteomics 2008; 7: 813-823.
120. Bunger S, Roblick UJ, Habermann JK,. Comparison of five commercial extraction kits for subsequent membrane protein profiling. Cytotechnology 2010; 61: 153-159.
121. Wilson ZE, Rostami-Hodjegan A, Burn JL, et al,. Inter-individual variability in levels of human microsomal protein and hepatocellularity per gram of liver. Br J Clin Pharmacol 2003; 56: 433-440.
122. von Richter O, Burk O, Fromm MF, Thon KP, Eichelbaum M, Kivisto KT,. Cytochrome P450 3A4 and P-glycoprotein expression in human small intestinal enterocytes and hepatocytes: a comparative analysis in paired tissue specimens. Clin Pharmacol Ther 2004; 75: 172-183.
123. +/ d -glucose cotransporter activity in mouse small intestine. J Pharm Pharmacol 2000; 52: 679-686.
124. Englund G, Jacobson A, Rorsman F, Artursson P, Kindmark A, Ronnblom A,. Efflux transporters in ulcerative colitis: decreased expression of BCRP (ABCG2) and Pgp (ABCB1). Inflamm Bowel Dis 2007; 13: 291-297.
125. Bianchi DW, Zickwolf GK, Yih MC, et al,. Erythroid-specific antibodies enhance detection of fetal nucleated erythrocytes in maternal blood. Prenat Diagn 1993; 13: 293-300.
126. George SP, Wang Y, Mathew S, Srinivasan K, Khurana S,. Dimerization and actin-bundling properties of villin and its role in the assembly of epithelial cell brush borders. J Biol Chem 2007; 282: 26528-26541.
127. Galetin A, Houston JB,. Intestinal and hepatic metabolic activity of five cytochrome P450 enzymes: impact on prediction of first-pass metabolism. J Pharmacol Exp Ther 2006; 318: 1220-1229.
128. Korjamo T, Monkkonen J, Uusitalo J, Turpeinen M, Pelkonen O, Honkakoski P,. Metabolic and efflux properties of Caco-2 cells stably transfected with nuclear receptors. Pharm Res 2006; 23: 1991-2001.
129. Lee C,. Proper estimation of basic transporter parameters in vitro: PhRMA IC50 Working Group Recommendations. International Transporter Consortium Workshop 2, National Harbor, Maryland: March 2012; Presentation http://www.ascpt.org/Portals/8/docs/Meetings/2012%20Annual%20Meeting/ 2012%20speaker%20presentations/ITCW2-MD%20C- MON%20SESSION%201%20TRANSPORT%20PHARMACOKINETICS.pdf
130. Mao Q, Unadkat JD,. Role of the breast cancer resistance protein (ABCG2) in drug transport. AAPS J 2005; 7: E118-E133.
131. Ozvegy C, Varadi A, Sarkadi B,. Characterization of drug transport, ATP hydrolysis, and nucleotide trapping by the human ABCG2 multidrug transporter. Modulation of substrate specificity by a point mutation. J Biol Chem 2002; 277: 47980-47990.
132. Romsicki Y, Sharom FJ,. The membrane lipid environment modulates drug interactions with the P-glycoprotein multidrug transporter. Biochemistry 1999; 38: 6887-6896.
133. Meier M, Blatter XL, Seelig A, Seelig J,. Interaction of verapamil with lipid membranes and P-glycoprotein: connecting thermodynamics and membrane structure with functional activity. Biophys J 2006; 91: 2943-2955.
134. Kararli TT,. Comparison of the gastrointestinal anatomy, physiology, and biochemistry of humans and commonly used laboratory animals. Biopharm Drug Dispos 1995; 16: 351-380.
135. Thwaites DT, Kennedy DJ, Raldua D, et al,. H/dipeptide absorption across the human intestinal epithelium is controlled indirectly via a functional Na/H exchanger. Gastroenterology 2002; 122: 1322-1333.
136. Taipalensuu J, Tavelin S, Lazorova L, Svensson AC, Artursson P,. Exploring the quantitative relationship between the level of MDR1 transcript, protein and function using digoxin as a marker of MDR1-dependent drug efflux activity. Eur J Pharm Sci 2004; 21: 69-75.
137. Makhey VD, Guo A, Norris DA, Hu P, Yan J, Sinko PJ,. Characterization of the regional intestinal kinetics of drug efflux in rat and human intestine and in Caco-2 cells. Pharm Res 1998; 15: 1160-1167.
138. Collett A, Stephens RH, Harwood MD, et al,. Investigation of regional mechanisms responsible for poor oral absorption in humans of a modified release preparation of the alpha-adrenoreceptor antagonist, 4-amino-6,7-dimethoxy-2-(5- methanesulfonamido-1,2,3,4 tetrahydroisoquinol-2-yl)-5-(2-pyridyl)quinazoline (UK-338,003): the rational use of ex vivo intestine to predict in vivo absorption. Drug Metab Dispos 2008; 36: 87-94.
139. Shoji T, Suzuki H, Kusuhara H, Watanabe Y, Sakamoto S, Sugiyama Y,. ATP-dependent transport of organic anions into isolated basolateral membrane vesicles from rat intestine. Am J Physiol Gastrointest Liver Physiol 2004; 287: G749-G756.
140. Loo TW, Bartlett MC, Clarke DM,. Disulfide cross-linking analysis shows that transmembrane segments 5 and 8 of human P-glycoprotein are close together on the cytoplasmic side of the membrane. J Biol Chem 2004; 279: 7692-7697.
141. Penny JI, Campbell FC,. Active transport of benzo[a]pyrene in apical membrane vesicles from normal human intestinal epithelium. Biochim Biophys Acta 1994; 1226: 232-236.
142. Neuhoff S, Artursson P, Ungell AL,. Advantages and disadvantages of using bovine serum albumin and/or Cremophor EL as extracellular additives during transport studies of lipophilic compounds across Caco-2 monolayers. J Drug Del Sci Tech 2007; 17: 259-266.
143. Uchida Y, Kamiie J, Ohtsuki S, Terasaki T,. Multichannel liquid chromatography-tandem mass spectrometry cocktail method for comprehensive substrate characterization of multidrug resistance-associated protein 4 transporter. Pharm Res 2007; 24: 2281-2296.
144. Watanabe T, Kusuhara H, Maeda K, et al,. Investigation of the rate-determining process in the hepatic elimination of HMG-CoA reductase inhibitors in rats and humans. Drug Metab Dispos 2010; 38: 215-222.
145. von Richter O, Glavinas H, Krajcsi P, Liehner S, Siewert B, Zech K,. A novel screening strategy to identify ABCB1 substrates and inhibitors. Naunyn Schmiedebergs Arch Pharmacol 2009; 379: 11-26.